February 3, 2025 10:04 AM EST
News Briefing

Tec­ton­ic to raise $185M; Ace­lyrin drops rights to Af­fi­body drug

ENDPOINTS

Plus, news about Im­munome, 89bio and Val­ne­va:

Tec­ton­ic’s $185M pri­vate place­ment: Af­ter a hec­tic week of stock swings, Tec­ton­ic Ther­a­peu­tic

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Drug prices like­ly to soar due to Trump tar­iffs, phar­ma bod­ies warn

Drug­mak­ers seize on bio­mark­ers to test the FDA's rare dis­ease shift

Pfiz­er says new col­orec­tal can­cer da­ta could sup­port full ap­proval of Braftovi

Ex­clu­sive: Ger­man biotech de­clares Phase 2 win for non-opi­oid drug for neu­ro­path­ic pain

J&J’s Ry­bre­vant gets CHMP back­ing weeks af­ter FDA re­jec­tion

Irish start­up re­ports mid-stage vic­to­ry for short-act­ing psy­che­del­ic drug in de­pres­sion

A service from the Financial Times